Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers

About this episode

The episode discusses the impact of multimodal aging signatures and proteomic biomarkers on multiple sclerosis care.

Guest: Adil Harroud, MD Guest: Dylan Hamitouche Host: Ryan Quigley Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS, a topic they presented on at the 2026 ACTRIMS Forum. Dr. Harroud is a neurologist and the co-leader of the Neuroimmunology Diseases Research Group at the Montreal Neurological Institute at McGill University. Mr. Hamitouche is a medical student at McGill University.

People in this episode

Host: Ryan Quigley

Guests: Adil Harroud, MD, Dylan Hamitouche, Adil Harroud

Topics covered

• multiple sclerosis
• aging signatures
• proteomic biomarkers
• risk stratification
• personalized treatment

Keywords

• multiple sclerosis
• aging signatures
• proteomic biomarkers
• risk stratification
• personalized treatment

Mentioned in this episode

Organizations: Montreal Neurological Institute, McGill University

More episodes of NeuroFrontiers

• Navigating Stem Cell Therapy Conversations in MS · June 8, 2026 · 5 min
• Cognitive Screening in MS: Practical Strategies and Modern Approaches · May 28, 2026 · 4 min
• Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role · May 14, 2026 · 15 min
• Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols · May 14, 2026 · 14 min
• Understanding Variability in Myasthenia Gravis · May 1, 2026 · 4 min
• Examining the Global Genetic Prevalence of TK2d · April 30, 2026 · 14 min